Skip to main content

Advertisement

SpringerLink
Log in

TROP2: a potential marker in diagnosis of thyroid neoplasms

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background and objectives

The human trophoblast cell surface antigen (TROP-2), a transmembrane glycoprotein, has recently been investigated as a valuable marker of thyroid epithelial neoplasms. In this study, we aimed to demonstrate the diagnostic utility of TROP2 in thyroid neoplasms.

Methods

A total of 308 cases, including 170 cases of different PTC variants, 50 cases of benign and non­neoplastic lesions, and 86 cases of other neoplasms (NIFT-P, poorly differentiated thyroid carcinoma, anaplastic thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, and medullary thyroid carcinoma), were included in this study. Only membranous staining with TROP2 was considered positive.

Results

In PTC, classical (n = 35), tall cell (n = 41), follicular (n = 39), solid (n = 19), hobnail (n = 10), Warthin-like (n = l0), columnar (n = 7), and oncocytic variant (n = 9) were 100%, 97.6%, 5.1%, 42.1%, 90%, 90%, 28.6%, and 33.3% positive, respectively. A negative reaction was observed in all 50 cases of benign and non-neoplastic lesions and also in surrounding normal thyroid tissue in all cases. Negative reactions were observed in 83 (n = 86) of other thyroid neoplasms including NIFT­P (n = 20), poorly differentiated thyroid carcinoma (n = 10), anaplastic thyroid carcinoma (n = 10), follicular thyroid carcinoma (n = 18), Hürthle cell carcinoma (n = 18), and medullary thyroid carcinoma (n = 10). Only focal positivity was observed in three Hürthle cell carcinoma cases.

Conclusion

TROP2 was a helpful marker for differentiating PTC, especially in the classic, tall cell, hobnail, and Warthin-like variants, benign and non-neoplastic lesions, and other neoplasms of the thyroid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schlumberger M, Leboulleux SJNRE (2021) Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol 17:176–188. https://doi.org/10.1038/s41574-020-00448-z

  2. Ma H, Xu S, Jin Y et al (2014) The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Pol J Pathol 65:202. https://doi.org/10.5114/pjp.2014.45782

  3. Nechifor-Boila A, Catana R, Loghin A et al (2014) Diagnostic value of HBME-1, CD56, galectin-3 and cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol 55:49–56

    Google Scholar 

  4. Barut F, Kandemir NO, Bektas S et al (2010) Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 21:80–89. https://doi.org/10.1007/s12022-010-9114-y

  5. de Matos LL, Del Giglio AB, Matsubayashi CO et al (2012) Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 7:1–10. https://doi.org/10.1186/1746-1596-7-97

  6. Wenqi D, Li W, Shanshan C et al (2009) EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 135:1277–1285. https://doi.org/10.1007/s00432-009-0569-5

  7. Cubas R, Li M, Chen C, Yao Q (2009) Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 1796:309–314. https://doi.org/10.1016/j.bbcan.2009.08.001

  8. Lipinski M, Parks DR, Rouse RV, Herzenberg LA (1981) Human trophoblast cell-surface antigens defined by monoclonal antibodies. PNAS 78:5147–5150. https://doi.org/10.1073/pnas.78.8.5147

  9. Liu H, Shi J, Lin F (2017) The potential diagnostic utility of TROP-2 in thyroid neoplasms. Appl Immunohistochem Mol Morphol 25:525. https://doi.org/10.1097/PAI.0000000000000332

  10. Simms A, Jacob RP, Cohen C, Siddiqui MT (2016) TROP‐2 expression in papillary thyroid carcinoma: potential diagnostic utility. Diagn Cytopathol 44:26–31. https://doi.org/10.1002/dc.23382

  11. Rapani E, Sacchetti A, Corda D, Alberti S (1998) Human Trop‐2 is a tumor‐associated calcium signal transducer. Int J Cancer Res 76:671–676. https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19980529)76:5%3C671::AID-IJC10%3E3.0.CO;2-7

  12. Alberti S, Miotti S, Stella M et al (1992) Biochemical characterization of Trop-2, a cell surface molecule expressed by human carcinomas: formal proof that the monoclonal antibodies T16 and MOv-16 recognize Trop-2. Hybridoma 11:539–545. https://doi.org/10.1089/hyb.1992.11.539

  13. Sukhthankar M, Alberti S, Baek SJ (2010) (−)-Epigallocatechin-3-gallate (EGCG) post-transcriptionally and post-translationally suppresses the cell proliferative protein TROP2 in human colorectal cancer cells. Anticancer Res 30:2497–2503

    CAS  Google Scholar 

  14. Mühlmann G, Spizzo G, Gostner J et al (2009) TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 62:152–158. https://doi.org/10.1136/jcp.2008.060590

  15. Fong D, Moser P, Krammel C et al (2008) High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 99:1290–1295. https://doi.org/10.1038/sj.bjc.6604677

  16. Fong D, Spizzo G, Gostner JM et al (2008) TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 21:186–191. https://doi.org/10.1038/modpathol.3801001

  17. Pak MG, Shin DH, Lee CH, Lee MK (2012) Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol 10:53. https://doi.org/10.1186/1477-7819-10-53

  18. Murtezaoglu AR, Gucer H (2017) Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19. Pol J Pathol 68:1. https://doi.org/10.5114/pjp.2017.67610

  19. Yang X, Hu Y, Shi H et al (2018) The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Eur Arch Oto-Rhino-L 275:2127–2134. https://doi.org/10.1007/s00405-018-5045-x

  20. Bychkov A, Sampatanukul P, Shuangshoti S, Keelawat S (2016) TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology 48:425–433. https://doi.org/10.1016/j.pathol.2016.04.002

  21. Guan H, Guo Z, Liang W et al (2017) Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer 17:1–10. https://doi.org/10.1186/s12885-017-3475-2

Download references

Funding

The research leading to these results received funding from Gaziantep University Scientific Research Projects Governing Unit (BAPYB).

Author information

Authors and Affiliations

  1. Department of Pathology, Gaziantep University Medical Faculty Hospital, Gaziantep, Turkey

    Zübeyir Turan & Suna Erkılıç

Authors
  1. Zübeyir Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suna Erkılıç
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zübeyir Turan.

Ethics declarations

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Gaziantep University (Date 06.05.2020/No. 2020171).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turan, Z., Erkılıç, S. TROP2: a potential marker in diagnosis of thyroid neoplasms. Ir J Med Sci 192, 99–103 (2023). https://doi.org/10.1007/s11845-022-02976-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-022-02976-1

Keywords

Search

Navigation